Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar PharmaLedger
In this Clinical Trial eRecruitment Use Case presentation, you will find:
An introduction to Clinical Trial eRecruitment use case presented by: Despina Daliani (Onorach) and Ken Nessel (Pfizer)
The current Clinical Trial Recruitment process
Pain points of the Clinical Trial eRecruitment
PharmaLedger’s Clinical Trial eRecruitment solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021PharmaLedger
Download PharmaLedger’s Spotlight Session presentations from DIA Europe 2021.
In addition to our 3D Virtual Booth that took place all week long at DIA Europe 2021, PharmaLedger hosted two 60-minute Spotlight Sessions.
Spotlight Session #1: PharmaLedger – Demonstrating the Vision of Blockchain Enabled Healthcare
Tuesday, March 16th the sessions kicks off with an introduction of the PharmaLedger project, followed by a look into our Electronic Product Information (ePI) and Anti-Counterfeiting use cases, then concluding with a full demonstration of our first prototype of the PharmaLedger ePI app. Speakers include PharmaLedger Industry Lead Daniel Fritz (Novartis), and ePI use case co-leads Patrick Maher (Novartis) and Ken Thursby (MSD).
Spotlight Session #2: PharmaLedger – Data Privacy and the Vision of a Blockchain Enabled Healthcare
Friday, March 19th following a PharmaLedger introduction, our partners explore how data privacy and blockchain are being used to shape the project and our patient-centric solutions, and look into how PharmaLedger is reshaping the informed consent process for clinical trials with our eConsent use case. Speakers include PharmaLedger Regulatory, Legal & Data Privacy Framework Co-Lead Nenad Georgiev (KU Leuven), eConsent use case co-lead Hernando Giraldo (Boehringer Ingelheim), and Baldwin Mak (Boehringer Ingelheim).
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
www.imi.europa.eu
Disclaimer: Any information on this article solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
Ομιλία - Παρουσίαση: “Βιοδείκτες: Η Κλινική τους Αξία και η Σχέση τους με τον ΕΟΠΥΥ”
Νικόλαος Τσούλος, MSc, MBA, Βιοχημικός, Διευθύνων Σύμβουλος GeneKor Medical SA
The way we bring new medicines to life is changing. Regulators, scientists and healthcare professionals are working together to ensure access to new medicines and other therapies is accelerated.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Writing A Phase I Protocol: A Multidisciplinary Team ApproachSGS
A well-written and thought-out protocol is essential for achieving a high quality research study. To write this complete protocol, one must involve multiple key players from different disciplines, including: pharmacokinetics, toxicology, statisticians, modeling and simulation, and a biomarkers specialist. This approach will take additional time and resources, however the time spent on writing a detailed protocol will help to avoid problems and delays during the study conduct and will make publishing the results easier. A complete protocol is also essential for the study to be approved by the ethics committee. This presentation will explain the important roles of each team member in writing an early phase protocol.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Clinical Trial eRecruitment | Topic #1 of PharmaLedger's 2nd Open Webinar PharmaLedger
In this Clinical Trial eRecruitment Use Case presentation, you will find:
An introduction to Clinical Trial eRecruitment use case presented by: Despina Daliani (Onorach) and Ken Nessel (Pfizer)
The current Clinical Trial Recruitment process
Pain points of the Clinical Trial eRecruitment
PharmaLedger’s Clinical Trial eRecruitment solution for the future state
Value added by PharmaLedger per actor involved
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
PharmaLedger’s Spotlight Session Presentations at DIA Europe 2021PharmaLedger
Download PharmaLedger’s Spotlight Session presentations from DIA Europe 2021.
In addition to our 3D Virtual Booth that took place all week long at DIA Europe 2021, PharmaLedger hosted two 60-minute Spotlight Sessions.
Spotlight Session #1: PharmaLedger – Demonstrating the Vision of Blockchain Enabled Healthcare
Tuesday, March 16th the sessions kicks off with an introduction of the PharmaLedger project, followed by a look into our Electronic Product Information (ePI) and Anti-Counterfeiting use cases, then concluding with a full demonstration of our first prototype of the PharmaLedger ePI app. Speakers include PharmaLedger Industry Lead Daniel Fritz (Novartis), and ePI use case co-leads Patrick Maher (Novartis) and Ken Thursby (MSD).
Spotlight Session #2: PharmaLedger – Data Privacy and the Vision of a Blockchain Enabled Healthcare
Friday, March 19th following a PharmaLedger introduction, our partners explore how data privacy and blockchain are being used to shape the project and our patient-centric solutions, and look into how PharmaLedger is reshaping the informed consent process for clinical trials with our eConsent use case. Speakers include PharmaLedger Regulatory, Legal & Data Privacy Framework Co-Lead Nenad Georgiev (KU Leuven), eConsent use case co-lead Hernando Giraldo (Boehringer Ingelheim), and Baldwin Mak (Boehringer Ingelheim).
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
www.imi.europa.eu
Disclaimer: Any information on this article solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
Ομιλία - Παρουσίαση: “Βιοδείκτες: Η Κλινική τους Αξία και η Σχέση τους με τον ΕΟΠΥΥ”
Νικόλαος Τσούλος, MSc, MBA, Βιοχημικός, Διευθύνων Σύμβουλος GeneKor Medical SA
The way we bring new medicines to life is changing. Regulators, scientists and healthcare professionals are working together to ensure access to new medicines and other therapies is accelerated.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Writing A Phase I Protocol: A Multidisciplinary Team ApproachSGS
A well-written and thought-out protocol is essential for achieving a high quality research study. To write this complete protocol, one must involve multiple key players from different disciplines, including: pharmacokinetics, toxicology, statisticians, modeling and simulation, and a biomarkers specialist. This approach will take additional time and resources, however the time spent on writing a detailed protocol will help to avoid problems and delays during the study conduct and will make publishing the results easier. A complete protocol is also essential for the study to be approved by the ethics committee. This presentation will explain the important roles of each team member in writing an early phase protocol.
Contact Us: clinicalresearch@sgs.com
Visit our Website: http://www.sgs.com/cro
Follow Us on LinkedIn: http://bit.ly/SGSLifeSciences
Alfredo Moscardini. BPI Group (UK). The EU Project “North East Productivity Alliance” and its role in transferring Lean knowledge from Nissan to companies in the North East of England. Lessons learned. Конференция «Удвоение производительности: опыт украинских компаний в применении лучших управленческих практик»
Арина Летягина. Управляющий бизнес изменениями и программами трансформации (сертифицированный LSS Black Belt, AXA Way University). Конференция «Удвоение производительности: опыт украинских компаний в применении лучших управленческих практик»
Success beyond numbers: The Salud Mesoamerica Initiative’s results-based fin...RBFHealth
The Salud Mesoamérica Initiative (SMI) is a public-private partnership between the Bill & Melinda Gates Foundation (BMGF), the Carlos Slim Foundation, the Government of Spain, the Inter-American Development Bank (IDB), the countries of Central America and the State of Chiapas in Mexico. SMI works to reduce maternal and health inequalities through a results-based financing model, aligned with priorities established by the governments of the region. Among the poor in Mesoamerica, only 5 out of every 10 pregnant women are attended during childbirth by skilled birth personnel and the mortality rate among children in poverty is twice that of the national average.
Renub Research has recently published a report named "Non-Invasive Prenatal Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2030," providing a detailed industry analysis that consists of market share insights. Furthermore, the report encompasses a study of competitors and regions and the recent growth in the Non-Invasive Prenatal Testing (NIPT) Market.
ILC webinar: Under the microscope: Comparing countries’ experiences of the CO...ILC- UK
COVID-19 has had devastating effects on health systems and economies across the world and has put the importance of the prevention of ill health throughout the life course into sharp focus– from the importance of better pandemic preparedness to the need to promote the overall health of the population.
This ILC webinar is part of our “Delivering prevention in an ageing world” programme.
The panellists presented their country perspectives on how each of their countries have responded to COVID-19 and what we can learn from the pandemic for the prevention agenda going forward.
Rahoitusinfo yrityksille 29.04.2021
Tervetuloa Turku Science Park Oy:n järjestämään rahoitusinfoon, jossa käydään läpi ajankohtaiset julkiset tukirahoitusmahdollisuudet yrityksille.
11.35 – 11.55 Ilmastorahaston tarjoamat rahoitusmahdollisuudet, Paula Laine, Ilmastorahasto
Rahoitusinfo yrityksille 29.04.2021
Tervetuloa Turku Science Park Oy:n järjestämään rahoitusinfoon, jossa käydään läpi ajankohtaiset julkiset tukirahoitusmahdollisuudet yrityksille.
10.45 – 11.15 EU – Horizon Europe, Cluster 5, Tom Warras, Business Finland
Rahoitusinfo yrityksille 29.04.2021
Tervetuloa Turku Science Park Oy:n järjestämään rahoitusinfoon, jossa käydään läpi ajankohtaiset julkiset tukirahoitusmahdollisuudet yrityksille.
10.05 – 10.25 ELY-keskuksen palvelut, rahoitus & elpymispaketin React EU-haku, Leevi Törmäkangas, ELY-keskus
Enterprise europe network rahoitusinfo 29.4.2021Business Turku
Rahoitusinfo yrityksille 29.04.2021
Tervetuloa Turku Science Park Oy:n järjestämään rahoitusinfoon, jossa käydään läpi ajankohtaiset julkiset tukirahoitusmahdollisuudet yrityksille.
11.15 – 11.35 Enterprise Europe Network (EEN), Olli Mankonen, Turku Science Park Oy
Kestävän ICT:n työpaja 12.3.2021 Tapio SalakoskiBusiness Turku
Työpajan teemana on ICT:n ympäristövaikutukset ja syyt, miksi digitaalisessa liiketoiminnassa kannattaa huomioida kestävän kehityksen tavoitteet.
Ohjelma:
Avaussanat - Timo Huttunen, Turku Science Park
"Digitalisaatio etenee, entä ymmärrys sen ympäristövaikutuksista?" - Lotta Toivonen, Sitra
"Kestävä ohjelmistokehitys alkaa EI:stä" - Johanna Andersen, Anders Innovations Oy
"Uudet liiketoimintamallit" - Sami Etula, Suomen vaikuttavuussijoitus Oy
"Isot jalat mutta lämmin käsi — kestävä ICT" - Tapio Salakoski, Turun yliopisto
Tilaisuuden päätössanat, Timo Huttunen
Kestävän ICT:n työpaja 12.3.2021 Lotta ToivonenBusiness Turku
Työpajan teemana on ICT:n ympäristövaikutukset ja syyt, miksi digitaalisessa liiketoiminnassa kannattaa huomioida kestävän kehityksen tavoitteet.
Ohjelma:
Avaussanat - Timo Huttunen, Turku Science Park
"Digitalisaatio etenee, entä ymmärrys sen ympäristövaikutuksista?" - Lotta Toivonen, Sitra
"Kestävä ohjelmistokehitys alkaa EI:stä" - Johanna Andersen, Anders Innovations Oy
"Uudet liiketoimintamallit" - Sami Etula, Suomen vaikuttavuussijoitus Oy
"Isot jalat mutta lämmin käsi — kestävä ICT" - Tapio Salakoski, Turun yliopisto
Tilaisuuden päätössanat, Timo Huttunen
Kestävän ICT:n työpaja 12.3.2021 Johanna AndersenBusiness Turku
Työpajan teemana on ICT:n ympäristövaikutukset ja syyt, miksi digitaalisessa liiketoiminnassa kannattaa huomioida kestävän kehityksen tavoitteet.
Ohjelma:
Avaussanat - Timo Huttunen, Turku Science Park
"Digitalisaatio etenee, entä ymmärrys sen ympäristövaikutuksista?" - Lotta Toivonen, Sitra
"Kestävä ohjelmistokehitys alkaa EI:stä" - Johanna Andersen, Anders Innovations Oy
"Uudet liiketoimintamallit" - Sami Etula, Suomen vaikuttavuussijoitus Oy
"Isot jalat mutta lämmin käsi — kestävä ICT" - Tapio Salakoski, Turun yliopisto
Tilaisuuden päätössanat, Timo Huttunen
Session 1: From Mine to Mining
BASF Battery Materials as a part of Europe’s and Finland sustainable battery value chain; Country Manager Tor Stendahl, BASF
Deep Company Interviews: Analysis & conclusionsBusiness Turku
Summary & conclusions + action proposals based on company interviews conducted during Oct. Nov. 2020.
Results from interviews.
Whole battery/electrification value chain.
Growth from the Electrification Business Ecosystem: Interview summariesBusiness Turku
Session 1: From Mine to Mining
Kick-off: Growth from the Electrification Business Ecosystem
First results and discoveries from Company Interviews. ==> conclusions and action proposals
Growth from the Electrification Business Ecosystem: SUMMARY AND FUTURE PLANS ...Business Turku
Summary & Future events: Growth from the Electrification Business Ecosystem
SUMMARY AND FUTURE PLANS & EVENTS
Johanna Valio, Yrityssalo Oy & Raimo Vuopionperä, Turku Science Park Oy
Sustainable production of battery chemicals from secondary resourceBusiness Turku
Session 3: From AI to Reuse & Recycling
Sustainable production of battery chemicals from secondary resources; CEO Kenneth Ekman, CrisolteQ Oy (A Fortum company)
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
18. CHINA
In March 5 2015, PerkinElmer Entered to
exclusive three-year agreement with
China’s National Health and Family
Planning Commission (NHFPC)
Training and educational
programs - > increase NBS
coverage
Introduce new technologies &
provide clinical training - >
drive panel expansion
19. EGYPT
2.7 million babies screened annually for
CH from 2012 onward with PerkinElmer
systems
The NBS laboratory in Cairo is the
largest in the world!
18 GSP instruments
Staff savings by consolidation of labs
and automation
Panel Expansion to PKU
implemented 2015
By method improvement to automated
GSP TSH (TRF) the false positive rate
has dropped from 10% to less than
0.3%
